Application No.: 10/581,534 Docket No.: 415852000200

REMARKS

Claim 10 has been amended to replace the term "compound" with "tubulin inhibitor" in response to the kind suggestion of Examiner Willis in the above mentioned telephone conference. Since the compounds in the cited document that putatively render the compounds of claim 10 obvious are disclosed as insulin secretion accelerators, not as tubulin inhibitors, this distinction was suggested by the Examiner to be included in the claims. Accordingly, claim 10 was amended to be limited to tubulin inhibitors. In accordance with this amendment, claim 14 and claim 23, which were also rejected, have corresponding amendments. It is believed that this amendment, then, places these claims in a position for allowance.

Claim 11 was merely objected to as dependent on claim 10. This has now been removed and thus claim 11 is clearly in a position for allowance as well as claim 21 dependent thereon.

Claim 24 was indicated as having allowable subject matter but objected to as dependent on an unallowed claim. Claim 24 has now been made independent and is thus in a position for allowance as are claims 25 and 27-28 dependent thereon.

Claims 28 and 30 were indicated as allowable.

Thus, in summary, claim 10 and claims 14 and 23 dependent thereon have been amended to be restricted to tubulin inhibitors and should be in a position for allowance. Claim 11 has been amended to place it in independent form and is thus allowable along with claim 21 dependent on it. Claim 12 and its dependent claim 22 are already allowed. Claim 24 has been amended to place it in independent form and is thus allowable along with the claims dependent thereon, claims 25, 27 and 28. Claims 29 and 30 were allowed.

The informality in claim 10 has also been corrected.

sd-540392

Application No.: 10/581,534 Docket No.: 415852000200

Withdrawn claims 15-20 are directed to methods of using the compositions of the now

allowed claims. Consideration of rejoinder of these claims and passage of these claims to allowance

is also respectfully requested.

Should additional issues arise with respect to rejoinder of these claims, a telephone call to

the undersigned is respectfully requested to discuss the possibility of amendment or cancellation of

these claims.

Conclusion

In view of the amendments to the claims, applicants respectfully request that claims 10-12

and 14-30 be passed to issue.

Should minor issues arise that could be settled over the phone, a telephone call to the

undersigned is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent

Office determines that an extension and/or other relief is required, applicants petition for any

required relief including extensions of time and authorize the Commissioner to charge the cost of

such petitions and/or other fees due in connection with the filing of this document to Deposit

Account No. 03-1952 referencing docket No. 415852000200.

Respectfully submitted,

Dated: December 6, 2010 By: / Kate H. Murashige /

Kate H. Murashige Registration No.: 29,959

MORRISON & FOERSTER LLP 12531 High Bluff Drive, Suite 100 San Diego, California 92130-2040

Telephone: (858) 720-5112 Facsimile: (858) 720-5125

sd-540392 10